Sesen Bio, after years on the edge of irrelevancy, scores speedy review for long gestating bladder cancer program
After years spent in the penny stock range, Sesen Bio has nabbed a long-awaited FDA review for its antibody-drug conjugate bladder cancer program.
The FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
